A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns

BMC Systems Biology

Volumn 7, Issue , 2013, Pages

  Bershteyn, Anna ^a   Eckhoff, Philip A ^a  

^a Intellectual Ventures Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ANTIVIRAL RESISTANCE; ARTICLE; BIOLOGICAL MODEL; COMPUTER SIMULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MEDICATION COMPLIANCE; PATHOPHYSIOLOGY; VIRUS LOAD;

ADENINE; ANTI-HIV AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MODELS, IMMUNOLOGICAL; ORGANOPHOSPHONATES; VIRAL LOAD;

MLCS; MLOWN;

EID: 84873169284     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-7-11     Document Type: Article

References (72)

1. Taylor S, Boffito M, Khoo S, Smit E, Back D. Stopping antiretroviral therapy. AIDS 2007, 21:1673-1682. 10.1097/QAD.0b013e3281c61394, 17690564.
2. Hurt CB, Eron JJ, Cohen MS. Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?. Clin Infect Dis 2011, 53:1265-1270. 10.1093/cid/cir684, 3246871, 21976467.
3. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, . On behalf of the CAPRISA 004 Trial Group Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 2010, 329:1168-1174. 10.1126/science.1193748, 3001187, 20643915, On behalf of the CAPRISA 004 Trial Group.
4. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D. Preexposure Prophylaxis for HIV Infection among African Women. N Eng J Med 2012, 367:411-422.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Eng J Med 2012, 367:423-434.
6. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Eng J Med 2012, 367:399-410.
7. Baggaley RF, Powers KA, Boily MC. What do mathematical models tell us about the emergence and spread of drug-resistant HIV?. Curr Opin HIV AIDS 2011, 6:131. 10.1097/COH.0b013e328343ad03, 3096989, 21505388.
8. Abbas UL, Anderson RM, Mellors JW. Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings. PLoS One 2007, 2:e875. 10.1371/journal.pone.0000875, 1975470, 17878928.
9. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP). PLoS One 2011, 6:e18165. 10.1371/journal.pone.0018165, 3078109, 21525976.
10. Supervie V, Barrett M, Kahn JS, Musuka G, Moeti TL, Busang L, Blower S. Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci Rep 2011, 1:11. 3216499, 22355530.
11. Supervie V, García-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci 2010, 107:12381-12386. 10.1073/pnas.1006061107, 2901470, 20616092.
12. Hoare A, Kerr SJ, Ruxrungtham K, Ananworanich J, Law MG, Cooper DA, Phanuphak P, Wilson DP. Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia. PLoS One 2010, 5:e10981. 10.1371/journal.pone.0010981, 2882328, 20544022.
13. Marks AJ, Pillay D, McLean AR. The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns. J Theor Biol 2010, 262:1-13. 10.1016/j.jtbi.2009.09.017, 19766126.
14. Nowak MA, Bangham CRM. Population Dynamics of Immune Responses to Persistent Viruses. Science 1996, 272:74-79. 10.1126/science.272.5258.74, 8600540.
15. Wang G, Deem MW. Physical Theory of the Competition that Allows HIV to Escape from the Immune System. Phys Rev Lett 2006, 97:188106.
16. Ciupe SM, De Leenheer P, Kepler TB. Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection. J Theor Biol 2011, 277:55-66. 10.1016/j.jtbi.2011.01.050, 21315731.
17. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004, 53:696-699. 10.1093/jac/dkh162, 15044425.
18. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med 2012, 18:1378-1385. 10.1038/nm.2892, 3490032, 22941277.
19. Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance. J Acquir Immune Defic Syndr 2005, 39:272-283. 10.1097/01.qai.0000165907.04710.da, 15980686.
20. Huang Y, Wu H, Holden-Wiltse J, Acosta EP. A dynamic Bayesian nonlinear mixed-effects model of HIV response incorporating medication adherence, drug resistance and covariates. Ann Appl Stat 2011, 5:551-577. 10.1214/10-AOAS376, 3498098, 23162677.
21. Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc R Soc Lond B Biol Sci 2000, 267:835-843.
22. Cramer JA. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989, 261:3273-3277. 10.1001/jama.1989.03420220087032, 2716163.
23. Kenna LA, Labbé L, Barrett JS, Pfister M. Modeling and simulation of adherence: Approaches and applications in therapeutics. AAPS J 2005, 7:E390-E407. 10.1208/aapsj070240, 2750977, 16353919.
24. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang C-J, Buono D, Eckholdt H, Howard AA, Schoenbaum EE. Antiretroviral Therapy Adherence and Viral Suppression in HIV-Infected Drug Users: Comparison of Self-Report and Electronic Monitoring. Clin Infect Dis 2001, 33:1417-1423. 10.1086/323201, 2692641, 11550118.
25. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, Wenger NS. A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors. Ann Intern Med 2001, 134:968-977. 10.7326/0003-4819-134-10-200105150-00011, 11352698.
26. Sedaghat AR, Wilke CO. Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy. Biol Direct 2011, 6:42. 10.1186/1745-6150-6-42, 3203257, 21910865.
27. Yi S, Nelson PW, Ulsoy AG. ASME Dynamic Systems and Control Conference (DSCC2008) October 20-22, 2008 2008, 1549-1557. Ann Arbor, Michigan, USA.
28. Elliott E. Estimates of error rates for codes on burst-noise channels. Bell Syst Tech J 1963, 42:1977-1997.
29. Gilbert EN. Capacity of a burst-noise channel. Bell Syst Tech J 1960, 39:1253-1265.
30. Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys Chem 1977, 81:2340-2361.
31. Gillespie DT. Stochastic Simulation of Chemical Kinetics. Annu Rev Phys Chem 2007, 58:35-55. 10.1146/annurev.physchem.58.032806.104637, 17037977.
32. Nowak MA, May RMC. Virus dynamics: mathematical principles of immunology and virology 2000, USA: Oxford University Press.
33. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol 2002, 2:28-36. 10.1038/nri700, 11905835.
34. Wodarz D, Nowak MA. Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immuno-suppressive infections and their treatment. Philos Trans R Soc B Biol Sci 2000, 355:1059-1070.
35. Grant MD, Smaill FM, Singal DP, Rosenthal KL. The influence of lymphocyte counts and disease progression on circulating and inducible anti-HIV-1 cytotoxic T-cell activity in HIV-1-infected subjects. AIDS 1992, 6:1085. 10.1097/00002030-199210000-00004, 1361339.
36. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, Sabbaghian MS, Ehler L, Prussin C, Stevens R, Lambert L, Altman J, Hallahan CW, De Quiros JCLB, Connors M. Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors. J Immunol 2000, 165:1082-1092.
37. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ. Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA. Science 1998, 279:2103-2106. 10.1126/science.279.5359.2103, 9516110.
38. The International HIV Controllers Study The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science 2010, 330:1551-1557. 3235490, 21051598, The International HIV Controllers Study.
39. Fideli T, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, Mulenga J, Kasolo F, Vermund SH, Aldrovandi GM. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001, 17:901-910. 10.1089/088922201750290023, 2748905, 11461676.
40. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188. 10.1038/387183a0, 9144289.
41. Rong L, Perelson AS. Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy. PLoS Comput Biol 2009, 5:e1000533. 10.1371/journal.pcbi.1000533, 2752194, 19834532.
42. Dixit NM, Perelson AS. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol 2004, 226:95-109. 10.1016/j.jtbi.2003.09.002, 14637059.
43. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 2011, 66:240-250. 10.1093/jac/dkq447, 3019086, 21118913.
44. Hawkins T, Veikley W, St Claire RL, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005, 39:406-411. 10.1097/01.qai.0000167155.44980.e8, 16010161.
45. Jullien V, Tréluyer J-M, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S. Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy. Antimicrob Agents Chemother 2005, 49:3361-3366. 10.1128/AAC.49.8.3361-3366.2005, 1196246, 16048948.
46. Sampah MES, Shen L, Jilek BL, Siliciano RF. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci 2011,
47. Chou T-C. Relationships between inhibition Constants and Fractional Inhibition in Enzyme-Catalyzed Reactions with Different Numbers of Reactants, Different Reaction Mechanisms, and Different Types and Mechanisms of Inhibition. Curr Mol Pharmacol 1974, 10:235-247.
48. Abu-Raddad LJ, Longini IA. No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 2008, 22:1055-1061. 10.1097/QAD.0b013e3282f8af84, 18520349.
49. Pilcher C, Tien H, Eron J, Vernazza P, Leu S, Stewart P, Goh L, Cohen M. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004, 189:1785-1792. 10.1086/386333, 15122514.
50. Lavreys L, Baeten JM, Chohan V, McClelland RS, Hassan WM, Richardson BA, Mandaliya K, Ndinya-Achola JO, Overbaugh J. Higher Set Point Plasma Viral Load and More-Severe Acute HIV Type 1 (HIV-1) Illness Predict Mortality among High-Risk HIV-1-Infected African Women. Clin Infect Dis 2006, 42:1333-1339. 10.1086/503258, 16586394.
51. Lavreys L, Baeten JM, Overbaugh J, Panteleeff DD, Chohan BH, Richardson BA, Mandaliya K, Ndinya-Achola JO, Kreiss JK. Virus Load during Primary Human Immunodeficiency Virus (HIV) Type 1 Infection Is Related to the Severity of Acute HIV Illness in Kenyan Women. Clin Infect Dis 2002, 35:77-81. 10.1086/340862, 12060878.
52. Kumwenda JJ, Makanani B, Taulo F, Nkhoma C, Kafulafula G, Li Q, Kumwenda N, Taha TE. Natural History and Risk Factors Associated with Early and Established HIV Type 1 Infection among Reproductive-Age Women in Malawi. Clin Infect Dis 2008, 46:1913-1920. 10.1086/588478, 18462100.
53. Kaufmann GR, Cunningham P, Kelleher AD, Zaunders J, Carr A, Vizzard J, Law M, Cooper DA. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. J Infect Dis 1998, 178:1812. 10.1086/314480, 9815241.
54. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral Dynamics of Acute HIV-1 Infection. J Exp Med 1999, 190:841-850. 10.1084/jem.190.6.841, 2195636, 10499922.
55. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS. Modeling Plasma Virus Concentration during Primary HIV Infection. J Theor Biol 2000, 203:285-301. 10.1006/jtbi.2000.1076, 10716909.
56. De Boer RJ, Perelson AS. Target cell limited and immune control models of HIV infection: a comparison. J Theor Biol 1998, 190:201-214. 10.1006/jtbi.1997.0548, 9514649.
57. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, Addo MM, Brumme C, Routy J-P, Little S, Jessen HK, Kelleher AD, Hecht FM, Sekaly R-P, Rosenberg ES, Walker BD, Carrington M, Altfeld M. Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells. J Virol 2009, 83:7641-7648. 10.1128/JVI.00182-09, 2708622, 19458000.
58. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB. A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science 2007, 317:944-947. 10.1126/science.1143767, 1991296, 17641165.
59. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003, 17:2581. 10.1097/00002030-200312050-00005, 14685052.
60. Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, Estes JD, Hahn BH, Hirsch VM, Kaur A, Kirchhoff F, Muller-Trutwin M, Pandrea I, Schmitz JE, Silvestri G. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 2009, 15:861-865. 10.1038/nm.2013, 2782707, 19661993.
61. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD. Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus-infected Macaques. J Exp Med 1999, 189:991-998. 10.1084/jem.189.6.991, 2193038, 10075982.
62. Madden LJ, Zandonatti MA, Flynn CT, Taffe MA, Cecilia M, Marcondes G, Schmitz JE, Reimann KA, Henriksen SJ, Fox HS. CD8+ cell depletion amplifies the acute retroviral syndrome. J Neurovirol 2004, 10:58-66.
63. Lindbäck S, Karlsson AC, Mittler J, Blaxhult A, Carlsson M, Briheim G, Sönnerborg A, Gaines H. Viral dynamics in primary HIV-1 infection. AIDS 2000, 14:2283-2291. 10.1097/00002030-200010200-00009, 11089616.
64. De Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, Roos M, Coutinho R, Miedema F, Goudsmit J. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997, 11:1799. 10.1097/00002030-199715000-00003, 9412697.
65. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma. Science 1996, 272:1167-1170. 10.1126/science.272.5265.1167, 8638160.
66. O'Brien TR, Blattner WA, Waters D, Eyster ME, Hilgartner MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Miley WJ, Kroner BL, Goedert JJ. Serum HIV-1 RNA Levels and Time to Development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996, 276:105-110. 10.1001/jama.1996.03540020027025, 8656501.
67. Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, Lamy P, Flaherty J, Coakley D, Di Mascio M. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003, 17:1151. 10.1097/00002030-200305230-00006, 12819516.
68. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001, 45:2733. 10.1128/AAC.45.10.2733-2739.2001, 90724, 11557462.
69. Van Rompay KK, Johnson JA, Blackwood EJ, Singh RP, Lipscomb J, Matthews TB, Marthas ML, Pedersen NC, Bischofberger N, Heneine W, North TW. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 2007, 4:25. 10.1186/1742-4690-4-25, 1852805, 17417971.
70. Fraser C, Hollingsworth TD, Chapman R, De Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: Epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci 2007, 104:17441-17446. 10.1073/pnas.0708559104, 2077275, 17954909.
71. Dorman KS, Zhou H. A branching process model of drug resistant HIV. Deterministic And Stochastic Models Of AIDS Epidemics And HIV Infections With Intervention 2005, 457-496. WORLD SCIENTIFIC.
72. Chun T-W, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo Y-H, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188. 10.1038/387183a0, 9144289.